Racivir

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name

Racivir

DrugBank Accession Number

DB12753

Background

Racivir, also known as RCV, is an oxothiolane nucleoside reverse transcriptase inhibitor similar to emtricitabine and lamivudine. Racivir is a 50:50 mixture of emtricitabine and its positive enantiomer. Racivir has been used in trials studying the prevention of HIV Infections.

Type

Small Molecule

Groups

Investigational

Structure

Similar Structures

Weight: Average: 247.24
Monoisotopic: 247.042690531
Chemical Formula: C₈H₁₀FN₃O₃S

Synonyms

(+/-)-Emtricitabine
Emtricitabine, (+/-)-
RCV

External IDs

PSI-5004

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Target	Actions	Organism
UReverse transcriptase/RNaseH	inhibitor	Human immunodeficiency virus 1

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Adenovirus type 7 vaccine live	The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Racivir.
Anthrax vaccine	The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Racivir.
Bacillus calmette-guerin substrain connaught live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Racivir.
Bacillus calmette-guerin substrain russian BCG-I live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Racivir.
Bacillus calmette-guerin substrain tice live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Racivir.

Food Interactions

Not Available

Chemical Identifiers

UNII: Not Available
CAS number: 143491-54-7
InChI Key: XQSPYNMVSIKCOC-UHFFFAOYSA-N
InChI: InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)
IUPAC Name: 5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-4-imino-1,4-dihydropyrimidin-2-ol
SMILES: OCC1OC(CS1)N1C=C(F)C(=N)N=C1O

References

General References

Not Available

External Links

Human Metabolome Database: HMDB0251822
PubChem Substance: 347911373
ChemSpider: 8013489
ChEMBL: CHEMBL161381
Wikipedia: Racivir

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.268 mg/mL	ALOGPS
logP	-0.3	ALOGPS
logP	0.082	Chemaxon
logS	-3	ALOGPS
pKa (Strongest Acidic)	5.47	Chemaxon
pKa (Strongest Basic)	0.56	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	6	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	89.14 Å²	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	66.78 m³·mol^-1	Chemaxon
Polarizability	21.9 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features